AstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.
List view / Grid view
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.
Eleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
Biopharma companies that experienced strong revenue growth due to COVID-19 drug sales have been overtaken by companies that developed obesity drugs in 2023, GlobalData suggests.